paradigm: panitumumab superior to bevacizumab as 1l treatment of patients with ras wt mcrc
Published 2 years ago • 219 plays • Length 1:28Download video MP4
Download video MP3
Similar videos
-
2:42
paradigm: panitumumab versus bevacizumab in ras-wt mcrc
-
2:43
paradigm: panitumumab plus mfolfox6 in ras wt mcrc
-
1:05
how will the paradigm trial change the mcrc treatment landscape?
-
0:33
panitumumab mfolofox6 as the new standard of care for ras wt metastatic colorectal cancer
-
6:12
panitumumab significantly improves os vs bevacizumab mfolfox6 in patients with ras wt and left...
-
1:40
mfolfoxiri/pan vs mfolfox6/pan as initial treatment of patients with unresectable ras & braf wt mcrc
-
3:01
deeper: m-folfoxiri and cetuximab versus bevacizumab in mcrc
-
7:28
expert report on panitumumab for first line treatment of ras wild type mcrc from asco 2022
-
2:50
comment: panitumumab plus mfolfox6 improves os for ras wild-type left sided mcrc
-
2:10
anti-egfr therapy for ras wild-type left-sided colorectal cancer
-
7:46
asco2022 - lba1: panitumumab mfolfox6 vs bevacizumab plus mfolfox6 1st-line in ras wt mcrc (p...
-
2:40
folfoxiri plus panitumumab vs mfolfox6/pan for unresectable ras and braf wild-type mcc
-
2:20
what is the best treatment for ras wild-type metastatic colorectal cancer?
-
5:05
is front-line anti-egfr therapy essential in ras-wt mcrc?
-
0:55
phase 3 paradigm trial review | anwaar saaeed, md | asco22 colorectal cancer updates
-
1:43
nivolumab, ipilimumab and panitumumab in mcrc
-
3:59
asco 2013: cetuximab superior to bevacizumab for advanced colorectal cancer
-
4:16
fire-3 study: cetuximab versus bevacizumab in metastatic colorectal cancer
-
1:02
paradigm: acquired gene alterations and progressive disease in crc